Diuretics: pharmacology, classes, uses, adverse effects and nursing considerations
On this page
01
Overview
Core Pharmacology
Diuretics increase renal sodium excretion (natriuresis); water follows sodium, producing diuresis. They rapidly relieve oedema and pulmonary congestion, but they do not replace disease-modifying heart-failure therapy. Correct class selection, fluid assessment and electrolyte monitoring are what make them safe. The core principle: where sodium goes, water follows — a diuretic is a sodium-management drug, not simply a “urine-making” drug.
02
Learning objectives
- Locate each diuretic class on the nephron and state its target transporter.
- Select the appropriate class for heart-failure congestion, hypertension and specific indications.
- Anticipate the characteristic adverse-effect profile of each class.
- Apply a safe sequence for diuretic use in heart failure.
- Specify the nursing monitoring and patient education that keeps diuretics safe.
03
The renal map
Scroll the table sideways on a smaller screen.
| Nephron site | Drug class | Target | Key effect |
|---|---|---|---|
| Proximal tubule | Carbonic anhydrase inhibitor | Carbonic anhydrase | Bicarbonate-rich urine; weak diuresis |
| Thick ascending limb | Loop diuretic | Na-K-2Cl cotransporter (NKCC2) | Most powerful natriuresis; calcium and magnesium loss |
| Early distal tubule | Thiazide / thiazide-like | Na-Cl cotransporter (NCC) | Moderate diuresis; calcium retention |
| Collecting duct | Potassium-sparing | Aldosterone receptor or ENaC | Mild diuresis; potassium retention |
| Whole nephron | Osmotic | Filtered osmoles | Water loss; expands extracellular fluid first |
04
Classification
Scroll the table sideways on a smaller screen.
| Class | Examples | Best for |
|---|---|---|
| Loop diuretics | Furosemide, bumetanide, torsemide | Acute pulmonary oedema, significant HF congestion, severe oedema, low eGFR |
| Thiazides | Hydrochlorothiazide, chlorthalidone, indapamide | Hypertension; add-on to loops for resistant oedema |
| Mineralocorticoid receptor antagonists | Spironolactone, eplerenone | Potassium-sparing; disease-modifying in eligible HFrEF — not merely “weak diuretics” |
| Other potassium-sparing | Amiloride, triamterene | ENaC blockade; use with potassium-wasting drugs |
| Others | Acetazolamide, mannitol, vaptans | Specialist indications |
05
Loop diuretics
Mechanism: NKCC2 blockade in the thick ascending limb stops Na-K-Cl reabsorption. Loops are “high-ceiling” — larger doses create greater natriuresis — but safety limits remain.
- Acute pulmonary oedema: furosemide 20–40 mg IV in diuretic-naïve adults (dose individualised).
- Chronic oedema: oral furosemide, bumetanide or torsemide at the lowest dose maintaining euvolaemia.
- Adverse effects: hypotension, AKI/azotaemia, hypokalaemia, hypomagnesaemia, hyponatraemia, alkalosis, gout, ototoxicity (risk rises with rapid IV administration, high doses and renal impairment).
06
Thiazide diuretics
Mechanism: NCC inhibition in the early distal convoluted tubule. Blood pressure falls initially through sodium/water loss, later through reduced peripheral resistance.
- Best uses: hypertension, mild oedema, nephrogenic diabetes insipidus, calcium-stone prevention in hypercalciuria, and add-on “sequential nephron blockade” when loop response is poor.
- Adverse effects: hypokalaemia, hyponatraemia, hypomagnesaemia, dehydration, hyperuricaemia/gout, hyperglycaemia, photosensitivity, erectile dysfunction.
- Calcium: thiazides reduce urinary calcium (loops increase it) — a favourite exam discriminator.
- Safety: severe hyponatraemia presents with confusion, seizure or collapse — check sodium urgently in an unwell patient.
07
Potassium-sparing diuretics
Scroll the table sideways on a smaller screen.
| Subgroup | Examples | Mechanism | Major caution |
|---|---|---|---|
| Aldosterone antagonist (MRA) | Spironolactone, eplerenone | Blocks mineralocorticoid receptor | Hyperkalaemia, renal impairment; spironolactone can cause gynaecomastia |
| ENaC blocker | Amiloride, triamterene | Blocks epithelial sodium channel | Hyperkalaemia; avoid unsafe combinations |
MRAs improve outcomes in appropriately selected HFrEF patients. Check potassium and renal function before starting or increasing, and repeat after initiation and dose changes. Combining an MRA with an ACE inhibitor/ARB/ARNI or potassium supplements may be appropriate — but only with deliberate monitoring, not by accident.
08
Other examinable classes
- Acetazolamide: carbonic anhydrase inhibitor — bicarbonate loss and metabolic acidosis. Uses: glaucoma, acute mountain sickness, selected metabolic alkalosis. Adverse effects: paraesthesia, renal stones, sulfonamide-related reactions.
- Mannitol: osmotic diuretic for raised intracranial or intraocular pressure. Initially expands intravascular volume — can worsen pulmonary oedema; avoid in anuria, severe dehydration or uncontrolled heart failure.
- Vaptans: vasopressin antagonists producing aquaresis (water loss exceeding sodium loss); specialist use in selected hyponatraemia.
09
Heart failure sequence
- Confirm congestion: dyspnoea, orthopnoea, raised JVP, oedema, crackles, weight gain, hepatomegaly or pulmonary oedema.
- Check perfusion and BP. Cold, hypotensive patients may be in cardiogenic shock — escalate urgently rather than simply increasing the diuretic dose.
- Give a loop diuretic for fluid overload; reassess urine output and symptoms; monitor fluid balance and weight.
- If response is inadequate: review dose, adherence, absorption, renal function, salt intake, NSAIDs and the diagnosis; sequential nephron blockade is prescribed by experienced clinicians with closer electrolyte checks.
- Once euvolaemic: use the lowest maintenance loop dose and optimise disease-modifying HFrEF therapy.
Diuretics mainly improve symptoms and prevent congestion-related admission; they do not by themselves reverse the cardiomyopathy.
10
Nursing monitoring
Scroll the table sideways on a smaller screen.
| Monitor | Why it matters | Escalate urgently if |
|---|---|---|
| BP, pulse, postural symptoms | Over-diuresis causes hypotension and falls | Syncope, shock, symptomatic hypotension |
| Input/output, daily weight, oedema, lung sounds | Measures decongestion better than any single urine check | Worsening breathlessness or very low urine output |
| Na, K, Mg, creatinine/eGFR, bicarbonate | Detects electrolyte disturbance and renal injury | Severe K/Na disturbance, arrhythmia, confusion, seizure |
| Hearing (high-dose or rapid IV loops) | Early detection of ototoxicity | Tinnitus or sudden hearing change |
Patient education
- Give oral doses early in the day; explain expected nocturia if a late dose is unavoidable.
- Daily weight beats guesswork — agree an action plan for rapid gain, worsening oedema or breathlessness.
- Avoid self-medicating with NSAIDs — they blunt diuretics and worsen renal function.
- Never start potassium supplements or potassium-based salt substitutes without prescriber direction.
11
Drug summary table
Scroll the table sideways on a smaller screen.
| Drug | Dose (adult) | Indication | Adverse effects / cautions |
|---|---|---|---|
| Furosemide | Oedema: 20–40 mg oral/IV daily–BD, titrated; acute pulmonary oedema: 40 mg IV (20 mg if naïve); max varies with response | Heart-failure congestion, pulmonary oedema, renal oedema, resistant hypertension adjunct | Hypokalaemia, hypomagnesaemia, hyponatraemia, hypotension, AKI, gout, ototoxicity at high/rapid IV doses; “triple whammy” with ACE inhibitor + NSAID |
| Bumetanide | 1–2 mg oral/IV daily (1 mg ≈ 40 mg furosemide) | Alternative loop; better oral absorption in gut oedema | As for furosemide |
| Hydrochlorothiazide | 25–50 mg oral daily | Hypertension, mild oedema | Hyponatraemia, hypokalaemia, hyperglycaemia, hyperuricaemia/gout, photosensitivity |
| Chlorthalidone / indapamide | Chlorthalidone 12.5–25 mg daily; indapamide 2.5 mg daily (SR 1.5 mg) | Hypertension (long-acting thiazide-like) | As for HCTZ; long action demands vigilance for hyponatraemia |
| Spironolactone | HF (HFrEF): 25–50 mg daily; resistant hypertension: 25–50 mg daily; ascites: up to 100–400 mg daily in divided doses | HFrEF (mortality benefit), resistant hypertension, ascites, hyperaldosteronism | Hyperkalaemia, renal impairment, gynaecomastia (switch to eplerenone); check K⁺ and creatinine at baseline and after dose changes; avoid with K⁺ supplements |
| Eplerenone | 25–50 mg daily | HFrEF post-MI, hypertension when gynaecomastia limits spironolactone | Hyperkalaemia; fewer antiandrogenic effects |
| Amiloride | 5–10 mg daily (max 20 mg) | Add-on to potassium-wasting diuretics; Liddle syndrome | Hyperkalaemia, especially with ACE inhibitors or renal impairment |
| Acetazolamide | 250 mg oral BD–TDS; altitude sickness 125–250 mg BD | Glaucoma, acute mountain sickness, metabolic alkalosis, epilepsy adjunct | Metabolic acidosis, paraesthesia, renal stones, drowsiness; sulfonamide caution |
| Mannitol | 0.25–1 g/kg IV over 15–30 min | Raised intracranial pressure, cerebral oedema | Initial volume expansion can precipitate pulmonary oedema; avoid in anuria and congestive HF |
Doses are educational examples; individualise against local protocols, renal function and the current Uganda Clinical Guidelines.
12
Clinical scenario
Scenario 1 — Weakness after starting spironolactone
A 70-year-old man with HFrEF, already on an ACE inhibitor, is started on spironolactone 25 mg daily. Two weeks later he reports generalised weakness; ECG shows peaked T waves and potassium is 6.2 mmol/L. This is MRA-plus-ACE-inhibitor hyperkalaemia: withhold the spironolactone under prescriber direction, give urgent treatment for hyperkalaemia per the emergency protocol (calcium gluconate if ECG changes, insulin-dextrose, consider potassium binders), recheck renal function, and restart only with specialist guidance and close monitoring. The preventable step: baseline and follow-up potassium checks after every MRA initiation and dose change.
Scenario 2 — Dizzy and dry after IV furosemide
After IV furosemide for acute heart failure, a patient becomes dizzy on standing with a BP of 90/60, dry mucous membranes, low urine output and potassium 3.0 mmol/L. Suspect over-diuresis: assess perfusion, hold or reduce further diuretic under prescriber direction, correct fluids and potassium, and monitor daily weights to find the maintenance dose that keeps him euvolaemic rather than empty. Contrast this with the creatinine rise that accompanies successful decongestion — the bedside picture (cold vs warm, congested vs dry) decides the next move, not the number alone.
13
Key points
14
References
- SlideShare: Diuretics — pharmacology lecture (Library reference.)
- 2022 AHA/ACC/HFSA and 2021 ESC Heart Failure Guidelines (Library reference.)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics — diuretics (Library reference.)
- DailyMed: furosemide and hydrochlorothiazide prescribing information (Library reference.)
15
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.